PD-1/PD-L1-IN-42

PD-1/PD-L1-IN-42

• UNSPSC Description: PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy[1].
• Target Antigen: PD-1/PD-L1
• Type: Peptides
• Related Pathways: Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/pd-1-pd-l1-in-42.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N1[C@@H](CCC1)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CS)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCCN)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)N
• Molecular Weight: 1861.13
• References & Citations: [1]Tseng TS, et al. Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering. J Chem Inf Model. 2024;64(5):1615-1627.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported